Mediclav

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mediclav

Quick Facts

Property Description
Active Ingredients Amoxicillin and Clavulanic Acid
Pharmacological Class Beta-Lactam / Beta-Lactamase Inhibitor Combination Antibiotic
Common Forms Oral dosage forms (Tablet, Suspension) and Powder for Injection
Origin Semisynthetic antibiotic derivative
General Purpose Fighting susceptible bacterial infections, including resistant strains

What Type of Antibiotic is Mediclav (Co-amoxiclav)?

Mediterraneo is a branded example of a semisynthetic fixed-dose combination antibiotic classified as a beta-lactam / beta-lactamase inhibitor combination, belonging to the aminopenicillin group of anti-infective agents. The core formulation, Co-amoxiclav, is widely recognized for its essential role in addressing microbial resistance. This medicine belongs to a class of antibiotics used to treat infections caused by bacteria.

As a combination product, it fundamentally differs from single-agent penicillins, such as standard Amoxicillin, by providing enhanced protection. The fixed-dose nature ensures the two active components are formulated together, allowing the medicine to retain efficacy in scenarios involving common bacterial pathogens, such as treating a severe lower respiratory tract infection.

Composition and Available Forms of the Medicine

The medicine's composition is defined by its two active agents: Amoxicillin and Clavulanic Acid (prepared as Potassium Clavulanate). Amoxicillin provides the essential bactericidal activity, while Clavulanic Acid functions as a beta-lactamase inhibitor, an auxiliary compound that neutralizes the bacteria's defense mechanism. This antibiotic combination is an essential treatment available in common oral and injectable forms.

Co-amoxiclav is supplied in various oral dosage forms, such as film-coated tablets and powder for oral suspension, allowing for ingestion via the oral route. The combination is manufactured under brands like Augmentin and Clavulin worldwide, with subtle differentiations such as specialized coatings or flavors for various patient groups.

General Purpose: Why is Mediclav a Combination Drug?

The general purpose of the Amoxicillin / Clavulanic Acid combination is to maintain and enhance antibiotic effectiveness against bacterial infections, particularly those caused by resistant strains. The inclusion of the beta-lactamase inhibitor protects the Amoxicillin from destruction by bacterial enzymes. This protection is vital for the drug’s effectiveness.

This combined pharmacological action gives the medicine a significantly broader antimicrobial spectrum. This essential feature ensures the antibiotic remains functional against bacterial pathogens that have developed beta-lactamase enzymes, thereby offering a reliable therapeutic option.

Regulatory References

  1. FDA label for Amoxicillin and Clavulanate Potassium (DailyMed)
  2. WHO Model List of Essential Medicines
  3. WHO Essential Medicines List

What side effects are possible with Mediclav?

Possible side effects and safety information for Mediclav (Amoxicillin and Clavulanate Potassium)

Adverse Reaction Scope

Key adverse reaction categories: Gastrointestinal disturbances are the most common category, followed by skin and hypersensitivity reactions. High-level safety classification follows the International Council for Harmonisation (ICH) frequency bands.

Frequency Classification Key Adverse Reactions (System-Organ Class)
Very Common (>1 in 10) Diarrhea (Gastrointestinal)
Common (up to 1 in 10) Nausea, Vomiting (Gastrointestinal); Mucocutaneous Candidiasis (Infections)
Uncommon (up to 1 in 100) Skin rash, Pruritus, Urticaria (Skin); Dizziness, Headache (Nervous System); Indigestion (Gastrointestinal); Transient rise in hepatic enzymes (Hepatobiliary)
Rare (up to 1 in 1,000) Erythema Multiforme (Skin); Reversible Leukopenia, Thrombocytopenia (Blood)
Not Known Severe Allergic Reactions, Jaundice, Convulsions, Antibiotic-associated Colitis (Serious)

Serious Adverse Reactions and Restrictions

Serious adverse reactions: Severe and occasionally fatal hypersensitivity reactions (anaphylaxis, angioedema) have been reported, particularly in individuals with a history of penicillin allergy. Other serious, rare reactions include severe cutaneous adverse reactions (e.g., Stevens-Johnson syndrome), hepatitis, cholestatic jaundice, and Clostridium difficile-associated diarrhea (pseudomembranous colitis).

Safety-related restrictions or limitations: Mediclav is contraindicated in patients with a known hypersensitivity to penicillin or other beta-lactams, and in those with a history of liver dysfunction or jaundice associated with prior use of the drug. Caution is required in patients with renal impairment, as dosage adjustment may be necessary. Use is generally avoided in patients with suspected infectious mononucleosis due to the risk of a non-allergic rash.

Population-specific Safety Considerations

Hepatic events (liver dysfunction) are reported more frequently in males and the elderly, and may be associated with prolonged treatment, sometimes becoming apparent several weeks after stopping the medication. In pediatric patients, high doses have been associated with increased rates of diarrhea, and tooth discoloration has been reported (often reversible with dental cleaning). The clavulanic acid component's dose is typically limited to manage tolerability issues like vomiting and nausea.

Overdose and Emergency Response

The official regulatory profile for Mediclav (Amoxicillin and Clavulanic Acid) overdose focuses on specific documented physiological manifestations and mandated emergency response actions. While many reported cases of overdose are often asymptomatic, key clinical signs may include gastrointestinal symptoms and a disturbance of the fluid and electrolyte balances.

A serious, regulator-documented outcome associated with high-dose exposure is the potential for generalized convulsions or fits. This risk is specifically noted to be higher in patients who have impaired renal function or existing kidney problems. Furthermore, the presence of amoxicillin crystalluria is a documented physiological finding following high doses, which in rare instances has been shown to lead to acute renal injury or renal failure. Individuals with reduced urine output are particularly susceptible to this complication.

In any suspected overdose scenario, the mandated regulatory guidance is to seek immediate medical attention. If severe manifestations such as a seizure or fit occur, the official instruction is to contact emergency services immediately. Overdose management is primarily symptomatic and supportive. Official documents note that both active components can be removed from the circulation using haemodialysis. Monitoring for fluid and electrolyte balance is required, and during high-dose administration, maintaining adequate fluid intake and urinary output is officially recommended to minimize the risk of crystalluria.

Therapeutic Uses of Mediclav

What Mediclav Treats: Main Uses and Benefits

Mediclav (Co-amoxiclav) is used in clinical settings where patients experience symptoms related to susceptible bacterial infections across several key organ systems. The conditions commonly managed with this medication include lower respiratory tract infections, acute bacterial rhinosinusitis, acute otitis media, urinary tract infections, and various skin and soft tissue infections.

“This supportive therapy is applied in clinical settings that involve acute or unstable symptom patterns, contributing to improved comfort during periods of heightened symptoms.”

This combination is commonly used to help address symptom clusters that may become intense or disruptive. Mediclav provides supportive benefit which generally contributes to easing symptoms related to systemic imbalance and discomfort associated with these acute bacterial illnesses. It is relevant for managing symptoms that interfere with daily comfort and functional stability, assisting with maintaining functional stability when symptoms interfere with routine activities across both pediatric and adult patient groups.

Quick Fact: Relief for Acute Discomfort
This combination is commonly applied during phases when fever, localized pain, and purulent discharge become more noticeable due to bacterial infection, and may assist with easing symptoms that create noticeable physiological strain.

Eligibility and Restrictions for Use

The eligibility for using Mediclav (Amoxicillin/Clavulanic Acid) is defined by official regulatory labeling, which establishes specific population-eligibility rules. Use is permitted for adults, adolescents, and children who do not have documented non-eligibility conditions.

Contraindications and Restrictions

The medicine is contraindicated and must not be used in patients with the following:

  • History of severe hypersensitivity (e.g., anaphylaxis) to any beta-lactam antibiotic, including penicillins or cephalosporins.
  • History of hepatic dysfunction or cholestatic jaundice specifically associated with prior Amoxicillin/Clavulanic Acid use.

Restricted and Conditional Use

Population/Condition Eligibility Status (as per Official Labeling)
Renal Impairment Requires dose adjustment; specific high-strength forms are contraindicated in severe renal impairment (CrCl <30 mL/min).
Hepatic Impairment Use is restricted; not generally recommended in severe cases, and regular liver function monitoring is required.
Infectious Mononucleosis Use is not recommended due to a high risk of developing a generalized morbilliform rash.
Pregnancy Use is generally restricted and often avoided during the first trimester unless essential.
Lactation Generally compatible, but monitoring the infant for potential side effects (e.g., diarrhea) is recommended.

Eligibility also requires considering age. Use is generally established for children 3 months, but specific formulations have age-based limitations, and older adults require renal function assessment.

What should I know about interactions with other medicines?

Mediclav’s (Amoxicillin and Clavulanic Acid) official interaction profile is defined by effects on kidney clearance and pharmacodynamic interference with other medications. The interaction profile highlights several substances that require regulatory consideration.

Interactions Affecting Plasma Concentration

Co-administration with Probenecid is generally not recommended because this medicine competes for the same renal transporters as Amoxicillin. This transporter competition increases and prolongs the plasma concentration of Amoxicillin by reducing its clearance. The medicine also potentially reduces the renal clearance of Methotrexate, which may result in elevated plasma concentrations of Methotrexate and an increased risk of toxicity. This effect is considered more clinically significant in patients with existing renal impairment.

Pharmacodynamic Interactions

The antibiotic combination may affect the activity of other medicines. Co-administration with Oral Anticoagulants, such as Warfarin, may lead to a prolongation of the International Normalized Ratio (INR), necessitating procedural monitoring. Furthermore, this medicine has the potential to reduce the effectiveness of Oral Contraceptives containing estrogen or progestogen. Co-administration with Allopurinol is associated with an increased incidence of skin rash.

Food Administration

Official labeling recommends taking this medicine at the start of a meal. This timing is advised to minimize the possibility of gastrointestinal intolerance and has been shown to enhance the absorption of the Clavulanic Acid component.

Mechanism of Action

Irreversible Inhibition of Bacterial Cell Wall Synthesis

This primary mechanism involves the Amoxicillin molecule targeting and irreversibly deactivating Penicillin-Binding Proteins (PBPs), the bacterial enzymes that cross-link the peptidoglycan polymer. This molecular interference blocks the construction of the bacterial cell wall, triggering the cell's own internal defense mechanisms (autolysis) and leading directly to osmotic lysis and the resulting cessation of bacterial viability at the site of biological activity.

️ Functional Synergy to Overcome Enzymatic Resistance

This component of the mechanism is managed by Clavulanic Acid, which functions as a suicide inhibitor against bacterial beta-Lactamase Enzymes. By irreversibly neutralizing these defense enzymes, Clavulanic Acid prevents the degradation of Amoxicillin, thereby allowing Amoxicillin to maintain its intrinsic bactericidal function, which results in the mechanistic inclusion of beta-Lactamase-producing strains into the spectrum of activity. The drug's bactericidal mechanism is constrained by the bacterial physiological state, relying on the cell being in the active growth phase for its bactericidal action.

Dosage and Administration Information

Official Administration Routes and Dosing

Mediclav (Co-amoxiclav) is used either orally via tablets and reconstituted suspensions or intravenously through the powder for injection form. Administration follows the established dosing schedule and conditions for use.

The medicine is instructed to be taken at the start of a meal to enhance the absorption of the clavulanic acid component and minimize potential gastrointestinal upset. Standard adult dosing regimens for immediate-release tablets are generally structured as 500 mg every eight hours or 875 mg every twelve hours, based on the Amoxicillin content.

Use Duration and Specific Constraints

The duration of use is typically limited, and treatment should generally not be extended beyond 14 days without clinical re-evaluation. Different formulations, such as varying Amoxicillin-to-Clavulanic Acid ratios or immediate-release and extended-release tablets, are not considered substitutable on a milligram-for-milligram basis.

Specific procedural rules apply to certain populations. For instance, the 875 mg tablet strength is not recommended for use in patients with severe renal impairment (Glomerular Filtration Rate less than 30 mL/min). If a scheduled dose is missed, it should be taken immediately, but if it is almost time for the next scheduled dose, the missed dose must be skipped entirely to avoid taking a double dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Mediclav

Evidence for Lower Respiratory Tract and Skin Infections

This section summarizes the types of regulatory and peer-reviewed research that have evaluated Mediclav (Amoxicillin/Clavulanate) for certain infections of the lungs and skin. Studies conducted during periods of increased symptom activity, such as Community-Acquired Pneumonia (CAP) or acute episodes of cellulitis, examined the use of the antibiotic combination. Research focused on populations including adults and older adults, and studies monitored outcomes related to clinical success rates and microbiological eradication rates—that is, the measurement of bacterial clearance. Findings describe patterns observed in the studies related to the measurement of specific outcomes linked to inflammatory or irritative states, such as changes in body temperature.

The studies explored the use of this antibiotic combination in clinical situations where the causative bacteria may produce protective enzymes. Trials was evaluated in settings assessing outcomes reflecting daily functioning or activity level, such as the hospitalization rate. However, long-term effects are not fully established; follow-up durations were limited for many primary regulatory trials.

Studies for Ear, Sinus, and Urinary Infections

The research base for acute ear infections (AOM), acute sinus infections (ABRS), and urinary tract infections (UTI) also includes short-term comparative studies and Randomized Controlled Trials (RCTs). This evidence was evaluated in patient groups ranging from children to adults, often focusing on conditions characterized by fluctuating or episodic manifestations. For AOM in pediatric patients, studies explored outcomes capturing phases of heightened symptom activity, such as fever and ear pain. While research highlights changes measured during the study period, the studies face limitations. For instance, distinguishing true bacterial ABRS from viral causes may be challenging in the study design itself. Regarding UTI, the generalizability of some older trial results was associated with the evolving prevalence of localized resistance patterns.

Evidence Gaps and Areas of Uncertainty

The research contributes to the broader evidence landscape, but some uncertainties and limitations may affect how findings are interpreted. A major limitation is that results apply only to the populations studied under specific trial conditions. Furthermore, in clinical studies for conditions like ABRS, the difficulty in isolating the exact causative bacteria may introduce variability into the observed patterns. Sample sizes were modest in some older comparative studies, and the certainty remains low for long-term health outcomes beyond the treatment phase.

Frequently Asked Questions (FAQ)

Common questions about Mediclav (FAQ)


Q: Can Mediclav interfere with birth control pills?

A: Official product information indicates that Mediclav may affect the activity of oral contraceptives. Because of this potential for reduced effectiveness, the use of supplementary non-hormonal contraception may be something to consider when reviewing your medication plan. Patients are generally advised to consider this potential interaction.


Q: Is there a maximum time frame that Mediclav is typically prescribed for?

A: Regulatory documents state that treatment with Mediclav should generally not be extended beyond 14 days. If use beyond 14 days is being considered, it is typically done after a clinical re-evaluation of the patient's condition.


Q: What is the significance of the evolving prevalence of localized resistance patterns mentioned in the research summary?

A: The prevalence of localized resistance patterns is a clinically relevant factor that regulatory guidance mentions because it can affect how effective the drug is against certain types of bacteria. This variability highlights the importance of adhering to official guidelines on appropriate antibiotic use.


Q: Does Mediclav affect the body's natural gut bacteria?

A: Studies and official information indicate that Mediclav does affect the natural bacterial balance in the gut. This is evidenced by the most common side effect being diarrhea, and the fact that rare but serious events like Clostridium difficile-associated diarrhea have been reported. Taking the medicine can alter the body’s normal gut flora.


Q: How quickly can a person expect to notice the intended effects of Mediclav?

A: Pharmacokinetic data suggests that the drug typically reaches its maximum concentration in the blood within approximately one hour after administration. However, the time it takes to observe the full effect on the infection may take longer.


Q: How long does Mediclav typically stay in the body after the last dose?

A: Regulatory data indicates that the mean elimination half-life for both active components is approximately one hour. This means that the majority of the drug is generally eliminated from the body within several hours following the final dose.


Q: Does Mediclav have a risk of affecting a person's ability to drive or operate machinery?

A: The official product information mentions that the medicine can cause certain nervous system side effects. These include uncommon events such as dizziness and headache, and in rare cases, convulsions. Since these events may potentially impair concentration, they could affect a person's ability to drive or operate machinery.


Q: Can Mediclav cause changes in sleep patterns?

A: Official documents report that Mediclav can, in rare instances, cause central nervous system effects, including hyperactivity and agitation. While these effects are not common, they are noted as rare adverse reactions that could potentially disturb normal sleep patterns.


Q: What are the general guidelines for using Mediclav in older adults?

A: General regulatory guidelines state that a specific dose adjustment is not typically required for older adults. However, if there is evidence of reduced kidney function, the dose must be carefully considered and adjusted by a healthcare provider.


Q: Is Mediclav generally safe for people with known kidney issues?

A: Official labeling requires careful consideration for individuals with reduced kidney function. Dose adjustment is mandated for patients with renal impairment, and specific high-strength forms of the drug are not recommended for those with severe kidney impairment, specifically when the creatinine clearance is less than 30 mL/min.


Q: What information is available about using Mediclav during pregnancy or breastfeeding?

A: Regarding pregnancy, the drug is generally avoided during the first trimester unless a doctor considers it absolutely necessary. For breastfeeding, both active ingredients are known to pass into breast milk. Official guidance recommends monitoring the infant for potential side effects, such as diarrhea.


Q: Why do official documents mention the possibility of a change in liver function with Mediclav?

A: Official documents highlight the possibility of changes in liver function because uncommon events, such as a transient rise in liver enzymes, are reported. More rarely, serious liver events like cholestatic jaundice can occur. Because of this, monitoring of liver function is often emphasized, particularly in older adults and males.


Q: Does taking Mediclav require a person to drink more water than usual?

A: Regulatory precautions recommend that individuals maintain adequate fluid intake when using this medication. This precaution is in place to help reduce the possibility of amoxicillin crystalluria, which is the formation of crystals in the urine.


Q: What is the likelihood of developing a rash after starting Mediclav?

A: Official product information classifies skin rash as an uncommon side effect, meaning it may occur in up to 1 in 100 people. It is noted that the risk of hypersensitivity reactions, which includes rash, is significantly higher in individuals with a known history of allergy to penicillin.


Q: Do people typically experience stomach upset when they start taking Mediclav?

A: Gastrointestinal disturbances are the most common category of reported adverse events. Diarrhea is reported as very common (more than 1 in 10 people), and nausea and vomiting are classified as common (up to 1 in 10 people), confirming that stomach upset is a frequent occurrence.


Q: Is there a known link between Mediclav and changes in mood or anxiety?

A: Yes, official reports classify certain central nervous system effects, including agitation and anxiety, as rare adverse reactions to the medication. These are not common, but they are noted in the regulatory documents.


Q: Can Mediclav be taken on an empty stomach?

A: Official labeling advises taking the medication at the start of a meal. This timing is specifically recommended to help minimize the risk of gastrointestinal upset and to support the absorption of the clavulanic acid component.


Q: What happens in the body if too much Mediclav is taken?

A: Taking too much of the medication can lead to symptoms such as disturbances in the stomach and intestines, as well as an imbalance of bodily fluids and salts. In rare cases, the accumulation of amoxicillin crystals in the urine has been observed, which can potentially lead to kidney failure.


Q: What are the key points patients should discuss with their doctor before starting Mediclav?

A: Official patient information highlights several mandatory discussion points. These include informing the doctor about any prior history of severe allergic reactions to penicillins or other related antibiotics, any existing history of liver dysfunction, and whether the patient has or suspects they have infectious mononucleosis.


Q: Can Mediclav affect the results of common laboratory blood tests?

A: Yes, the clavulanic acid component of the medicine is known to potentially interfere with some lab tests. Specifically, it can lead to a non-specific binding reaction that may cause a false positive result on a test known as the Coombs test.


Q: What does the patient leaflet say about storing Mediclav in humid conditions?

A: The patient leaflet specifies that dry tablet and powder forms should be kept in the tightly closed original container at room temperature. The instructions explicitly mention that the product must be protected from moisture (humidity) and light to maintain its stability.


Q: Is the medication known to have a metallic taste or other taste disturbances?

A: Official reports indicate that taste disturbance, which can include a metallic or altered taste sensation (dysgeusia), has been reported. This effect has been noted in clinical trials involving amoxicillin-containing medication regimens.

How should Mediclav be stored and disposed of?

How to Store and Dispose of Mediclav (Amoxicillin/Clavulanate Potassium)

Mediclav requires specific, separate storage conditions based on its form to ensure stability, as detailed in regulatory labeling.


Storage Requirements

Product Form Temperature and Protection Condition
Dry Tablets/Powder Store at controlled room temperature (20 C to 25 C) in the tightly closed original container. Protect from moisture and light.
Reconstituted Suspension Must be stored in a refrigerator (2 C to 8 C). Do not freeze.

The reconstituted liquid suspension is stable for a maximum of 10 days when refrigerated, after which any unused portion must be discarded. Mediclav must be stored out of reach of children.

Disposal

Official disposal guidelines recommend returning unused or expired medicine through a drug take-back program. If this is unavailable, the product should be mixed with an undesirable substance (e.g., used coffee grounds) and sealed in a container before being placed in household trash, in accordance with local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mediclav found in:

A-Z Index: